Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: This study describes clinical characteristics, treatment patterns as well as safety outcomes of NSCLC patients harboring PD-L1 ≥ 50% who received adjuvant atezolizumab within the Italian real-world scenario. METHODS: Patients with surgically resected NSCLC harboring EGFR/ALK wild type disease and PD-L1 TPS ≥ 50%, who received at least one cycle of adjuvant atezolizumab were included. Clinical-pathological and molecular data, safety and efficacy outcomes were collected from the Italian ATLAS real-world registry. RESULTS: A total of 132 patients were included across 45 Italian centers between July 2022 and August 2024. Lobectomy was performed in 81.1% of cases, with 8.3% pathological stage IIA, 40.2% stage IIB, 43.9% stage IIIA, and 7.6% stage IIIB, according to the eighth TNM staging edition. The median number of atezolizumab cycles was 12.5 (range: 1-20). Treatment related adverse events (TRAEs) during atezolizumab were reported in 44 patients (33.3%), including 11 (8.3%) who experienced multiple TRAEs. Grade ≥ 3 TRAEs were reported in 21 cases (15.9%), leading to treatment discontinuation in 18 (13.6%). The median time to the first onset of TRAEs was 89 days (range: 3-390 days). 15 patients experienced a disease recurrence, including 6 locoregional-only and 9 distant relapses, with a median time since surgery of 13.3 months. CONCLUSION: This study showed that the safety profile of adjuvant atezolizumab outside of a clinical trial context was comparable to the IMPower-010 study, highlighting the value of the Italian ATLAS registry as source of real-word evidence to optimize the clinical management of NSCLC patients.
Source: The Oncologist
Authors: Francesco Passiglia, Maria Lucia Reale, Giulia Pasello, Giuseppe Viscardi, Ilaria Attili, Francesca Mazzoni, Domenico Galetta, Chiara Catania, Kallopi Andrikou, Alessandro Russo, Tiziana Vavala, Alessandra Bulotta, Lorenzo Calvetti, Anna Maria Carta, Salvatore Grisanti, Sabrina Mariotti, Giulia La Cava, Alessandra Dodi, Vieri Scotti, Teresa Del Giudice, Gabriele Minuti, Elio Gregory Pizzutillo, Rita Chiari, Carminia Maria Della Corte, Carlo Genova, Giuseppe Lo Russo, Daniele Pignataro, Daniele Pozzessere, Elisa Roca, Luca Toschi, Chiara Bennati, Gloria Borra, Anna Bettini, Adolfo Favaretto, Alain Gelibter, Stefania Gori, Fabrizio Tabbò, Maria Pagano, Alberto Pavan, Lorenzo Belluomini, Luca Tondulli, Concetta Sergi, Brigida Stanzione, Umberto Malapelle, Silvia Novello, Emilio Bria
Institutions: Ospedale San Luigi Gonzaga, University of Turin, Ospedale Vito Fazzi, University of Padua, Istituto Oncologico Veneto, Ospedale Monaldi, European Institute of Oncology, Azienda Ospedaliero-Universitaria Careggi, Istituto Tumori Bari, Humanitas Gavazzeni, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, IRCCS Ospedale San Raffaele, Ospedale San Bortolo, Azienda Ospedaliera G. Brotzu, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, University of Rome Tor Vergata, Policlinico Tor Vergata, Università Campus Bio-Medico, University of Parma, Azienda Ospedaliero-Universitaria "Renato Dulbecco", Istituti di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori Regina Elena, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, University of Campania "Luigi Vanvitelli", Ospedale Policlinico San Martino, University of Genoa, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda Sanitaria Locale di Asti, Ospedale di Prato Santo Stefano, Azienda Usl Toscana Centro, Ospedale P. Pederzoli – Casa di Cura Privata S.p.a., IRCCS Humanitas Research Hospital, Ospedale "Santa Maria delle Croci" di Ravenna, Azienda Ospedaliero Universitaria Maggiore della Carita, Ospedale Papa Giovanni XXIII, AULSS 2 Marca Trevigiana, Ca' Foncello Hospital, Sapienza University of Rome, Ospedale Sacro Cuore Don Calabria, Ospedale Michele e Pietro Ferrero - Verduno, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Azienda Sanitaria dell'Alto Adige, Ospedale Garibaldi, Centro di Riferimento Oncologico, University of Naples Federico II, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,852
OpenAlex ID: W7117129583